secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001193125-25-043564
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio unveils gamma-delta T cell engager platform with lead candidate INB-619
------------------------------------------------------------------------------

- INB-600 platform expands both Vd1+ and Vd2+ T cells; lead INB-619 targets CD19 for B-cell cancers and autoimmune diseases.
- Preclinical data: up to 450-fold T cell expansion, rapid and sustained B-cell depletion with target cells eradicated.
- Natural lower IL-6 secretion may reduce risk of CRS and neurotoxicity vs. CAR-T and traditional TCEs.
- CEO cites unmet need for deep B-cell depletion with improved safety; plans to seek partners for IND-enabling trials.
- No CRS or neurotoxicities observed to date in IN8bio's ongoing gamma-delta T cell clinical programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525043564/0001193125-25-043564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525043564/d936231d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-043564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer